Peptide Vendor Closures 2025-2026: The Dated Record | Artemis Labs
Peptide Vendor Closures 2025-2026: Who Closed, When, and What the Record Shows
Published August 21, 2026 · Artemis Labs
Peptide vendor closures 2025-2026 — Between December 2024 and July 2026, US researchers lost Peptide Sciences and Amino Asylum, watched the Paradigm Peptides case end in prison sentences, and saw the FDA issue two multi-vendor warning-letter batches. This hub records each event with dates and sources, and links to a dedicated page for every entity.
Key findings
- Three major vendors are gone: Peptide Sciences (voluntary closure, March 6, 2026), Amino Asylum (dark since a June 2025 FDA raid), and Paradigm Peptides (offline since March 2024; its owner was sentenced July 30, 2026).
- Eleven entities drew FDA warning letters in two batches — four on December 10, 2024 and seven dated March 31, 2026 — each letter finding that products labeled research-use-only were intended as drugs for human use.
- Brand familiarity did not survive the period; verification did. Testing documentation, per-order COAs, and cited claims remained checkable at any vendor throughout — which is the doctrine this page closes on.
Peptide Sciences closed voluntarily in March 2026
Peptide Sciences — by industry traffic estimates the largest US research-peptide vendor, in a roughly $7.4-million-per-month revenue class — announced its closure on March 6, 2026, halted all order processing, and went offline shortly after. The company gave no detailed explanation; coverage noted the enforcement-wave backdrop without a stated cause. Its closure notice declared that any further sales under its brand are fraudulent, and unaffiliated sites reusing the branding have appeared since. The dated account and clone-site red flags are in the Peptide Sciences shutdown explainer; the criteria for choosing a successor are in Peptide Sciences alternatives: a verification-first framework.
Amino Asylum went dark after a June 2025 raid
Amino Asylum was raided by FDA agents at its warehouse facility around June 18, 2025 — the first physical raid on a major research-peptide vendor. The site went dark overnight, payment processing was terminated, and pending orders were frozen. Similarweb-class estimates put the site near 400,000 monthly visitors at the time. The founders’ legal outcomes have not been verified beyond the raid itself, and this record claims nothing further. What a raid means for a vendor’s customers — versus what a warning letter means — is examined in Amino Asylum alternatives, and the hour-by-hour consequences of a vendor going dark are in the Amino Asylum raid timeline.
Paradigm Peptides ended in guilty pleas and prison sentences
Paradigm Peptides’ site went down in March 2024. On December 10, 2025, owner Matthew Kawa pleaded guilty to introducing unapproved drugs into interstate commerce with intent to defraud and mislead, and to illegally importing merchandise; Jennifer Stechkober, his sister and the company’s main employee, also pleaded guilty. At sentencing on July 30, 2026 in South Bend (N.D. Indiana), Kawa received 70 months, one year of supervised release, and a $5 million forfeiture; Stechkober received 16 months. Court records show the products included peptides, hCG, and SARMs — and that products labeled as SARMs contained testosterone, a Schedule III substance. A similarly named domain (paradigmpeptides.is) later appeared, itself claiming no affiliation. The identity-verification lesson is drawn out in Paradigm Peptides alternatives.
December 2024: four warning letters in one day
FDA issued warning letters to four research-peptide sellers on December 10, 2024, all in the GLP-1 compound class, each with 15 working days to respond. The recipients were Summit Research Peptides (letter 695607-12102024), Prime Vitality Inc dba Prime Peptides (695156-12102024), Xcel Research LLC (694608-12102024), and SwissChems. In each case, FDA’s letter states that website and social-media evidence established the products were intended for human use despite research-use-only labeling — in Summit’s case citing the company’s own public Facebook post attaching therapeutic-outcome claims to a two-compound pairing, the clearest statement of FDA’s totality-of-evidence approach. Each recipient has a dedicated analysis: Summit Research Peptides (the social-media lesson), Prime Peptides (why a research-use disclaimer is no defense), Xcel Peptides (catalog breadth versus verification), and SwissChems (how to read an FDA warning letter).
March 2026: seven letters in a single batch
FDA warning letters dated March 31, 2026 and posted April 7, 2026 went to seven sites at once: Lovega LLC dba Pink Pony Peptides (Wellington, FL), Mile High Compounds LLC (Clifton, CO), Prime Sciences (Scottsdale, AZ), Gram Peptides (Rancho Santa Fe, CA), PekCura Labs (Pensacola, FL), FormPour (Canton, MI), and Guangzhou Huli Technology dba Fantasy Face (Chicago, IL). FDA’s stated position: despite research-use-only disclaimers, “evidence obtained from your website establishes that your products are intended to be drugs for human use.” The letters focus on therapeutic-effect descriptions and on administration supplies offered in the same shopping cart, and read coded product names such as “GLP-1 SM” and “GLP-3 RT” as circumvention, not cover. All seven entities, letter numbers, and the two documented triggers are detailed in the April 2026 FDA peptide warning letters explainer.
Where researchers go from here
The record above spans a voluntary closure, a raid, a criminal case, and eleven warning letters — different mechanisms, one common thread. In every case, what customers had relied on was the brand, and the brand is exactly what failed: names were reused by strangers, labels did not match contents, and research-use disclaimers did not describe what the sellers were actually doing. What never stopped being checkable was the evidence: who tests the material, whether a Certificate of Analysis accompanies each order, whether product claims trace to published literature, and whether the vendor discloses findings that cut against its own catalog.
That is the verification-first doctrine: judge every vendor — Artemis Labs included — against criteria that do not depend on trust in a name. The working tools are the supplier-evaluation checklist for research-peptide vendors and the guide to reading a Certificate of Analysis; the full dated chronology from December 2024 through July 2026 is kept as a standing reference in the peptide vendor enforcement timeline. Artemis Labs maintains its cited literature index at the Artemis Labs research library; every compound it supplies is for laboratory research use only.
Frequently asked questions
Which peptide vendors shut down in 2025-2026?
Peptide Sciences (announced March 6, 2026), Amino Asylum (dark since the June 2025 raid), and Paradigm Peptides (offline since March 2024, with its owner sentenced July 30, 2026) are the three major vendors gone from the market as of this writing.
Are FDA warning letters the same as a shutdown?
No — a warning letter is a documented FDA finding with a 15-working-day response requirement, not a closure order. The December 2024 and March 2026 batches document FDA’s findings about eleven entities; each entity’s subsequent status is its own question, tracked on the pages linked above.
How can a researcher verify a surviving vendor?
Verification runs on evidence, not reputation: confirm third-party HPLC and MS testing, expect a Certificate of Analysis with every order, follow the product-page citations to PubMed or DOI, check for counter-evidence disclosure, and confirm the vendor sells no administration supplies. The supplier-evaluation checklist linked above walks through each step.
Is more enforcement expected?
More than one hundred FDA warning letters have gone to peptide and research-use-only sellers since September 2025, per the FDA warning-letter database — a pace that makes the enforcement wave a standing condition of the market. Predictions beyond the documented record belong to the reader, not this page.
References
- Peptides Explorer — “Peptide Sciences Shut Down.” peptidesexplorer.com/blog/peptide-sciences-shut-down
- BioStrata Research — “Did Peptide Sciences Shut Down?” biostrataresearch.com
- PS Peptides — “What Happened to Amino Asylum Peptides.” pspeptides.com
- The Peptide Catalog — “Amino Asylum Shut Down: Alternatives.” thepeptidecatalog.com
- CBS News — “Peptides Seller Gets Prison Sentence for Unapproved Drugs” (U.S. Attorney’s Office, N.D. Indiana). cbsnews.com
- US FDA — Warning Letters database (December 10, 2024 letters 695607, 695156, 694608; March 31, 2026 letters 721088, 721600, 721805, 721806, 721709, 722215, 722228). fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
- Policy Canary — “FDA Research Peptide Warning Letters, April 2026.” policycanary.io
